View Older Stories View More Recent Stories

Jul 28, 2022 08:00AM CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
Jul 13, 2022 04:06PM CytomX Therapeutics (CTMX) Issues Strategic Update
Jul 13, 2022 04:05PM CytomX Therapeutics Provides Strategic Update
Jul 6, 2022 04:06PM CytomX Therapeutics (CTMX) Announces Phase 2 Study of Praluzatamab Ravtansine Met Primary Endpoint
Jul 6, 2022 04:05PM CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
Jun 16, 2022 08:00AM CytomX Therapeutics Announces New Employment Inducement Grants
Jun 1, 2022 08:00AM CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
May 26, 2022 08:00AM CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
May 5, 2022 04:15PM CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 28, 2022 08:00AM CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
Apr 14, 2022 04:17PM CytomX Therapeutics (CTMX) Announces Retirement of John A. Scarlett from Board
Apr 14, 2022 04:15PM CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
Mar 23, 2022 04:15PM CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
Mar 17, 2022 08:00AM CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
Mar 1, 2022 04:15PM CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
Feb 28, 2022 08:00AM CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
Feb 22, 2022 08:00AM CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
Feb 16, 2022 08:00AM CytomX Therapeutics Announces New Employment Inducement Grants
Feb 7, 2022 09:02AM CytomX Therapeutics (CTMX) Promotes Amy Peterson to COO
Feb 7, 2022 09:00AM CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer
Jan 20, 2022 08:00AM CytomX Therapeutics Announces New Employment Inducement Grants
Jan 19, 2022 08:01AM CytomX Therapeutics (CTMX) Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
Jan 19, 2022 08:00AM CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
Jan 5, 2022 08:00AM CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 20, 2021 04:06PM CytomX Therapeutics (CTMX) Reports Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029
Dec 20, 2021 04:05PM CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71
Nov 11, 2021 08:00AM CytomX Therapeutics to Present at Upcoming November Investor Conferences
Nov 4, 2021 04:15PM CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
Nov 1, 2021 08:00AM CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting
Oct 28, 2021 08:00AM CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021
Oct 18, 2021 08:00AM CytomX Therapeutics Announces New Employment Inducement Grants
Oct 4, 2021 08:09AM CytomX Therapeutics (CTMX) Appoints Alan Ashworth to its Board
Oct 4, 2021 08:00AM CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors
Sep 16, 2021 08:00AM CytomX Therapeutics Announces New Employment Inducement Grants
Sep 7, 2021 08:00AM CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Aug 17, 2021 08:00AM CytomX Therapeutics Announces New Employment Inducement Grants
Aug 5, 2021 04:15PM CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
Aug 4, 2021 08:00AM CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)
Aug 2, 2021 08:00AM CytomX Therapeutics to Present at Upcoming August Investor Conferences
Jul 29, 2021 08:00AM CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
Jun 21, 2021 08:00AM CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research
May 27, 2021 08:00AM CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 6, 2021 04:15PM CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
Apr 29, 2021 08:00AM CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021
Apr 14, 2021 04:01PM CytomX Therapeutics Announces New Employment Inducement Grants
Mar 24, 2021 08:00AM CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
Feb 24, 2021 04:15PM CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 22, 2021 08:00AM CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences
Feb 19, 2021 08:00AM CytomX Therapeutics Announces New Employment Inducement Grant
Feb 17, 2021 08:00AM CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
View More Recent Stories View Older Stories